$4.11
1.71% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US9840152063
Symbol
XBIO
Sector
Industry

Xenetic Biosciences, Inc. Stock price

$4.11
-0.09 2.16% 1M
-0.04 0.98% 6M
+0.66 19.10% YTD
+0.55 15.43% 1Y
-10.49 71.85% 3Y
-10.19 71.26% 5Y
-985.89 99.58% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.07 1.71%
ISIN
US9840152063
Symbol
XBIO
Sector
Industry

Key metrics

Market capitalization $6.34m
Enterprise Value $-500.00k
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.17
EV/Sales (TTM) EV/Sales -0.20
P/S ratio (TTM) P/S ratio 2.52
P/B ratio (TTM) P/B ratio 0.90
Revenue growth (TTM) Revenue growth 7.15%
Revenue (TTM) Revenue $2.52m
EBIT (operating result TTM) EBIT $-4.36m
Free Cash Flow (TTM) Free Cash Flow $-2.94m
Cash position $6.84m
EPS (TTM) EPS $-2.65
P/S forward 2.88
EV/Sales forward negative
Short interest 1.02%
Show more

Is Xenetic Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Xenetic Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Xenetic Biosciences, Inc.:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast Xenetic Biosciences, Inc.:

Hold
100%

Financial data from Xenetic Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
2.52 2.52
7% 7%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 3.66 3.66
5% 5%
145%
- Research and Development Expense 3.22 3.22
13% 13%
128%
-4.36 -4.36
10% 10%
-173%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -4.36 -4.36
10% 10%
-173%
Net Profit -4.08 -4.08
8% 8%
-162%

In millions USD.

Don't miss a Thing! We will send you all news about Xenetic Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Xenetic Biosciences, Inc. Stock News

Neutral
Accesswire
12 days ago
Reid Bissonnette, Ph.D, Executive Consultant for Translational Research and Development at Xenetic, discusses extension of its Research Agreement with the University of Virginia for the advancement of its DNase-Based oncology platform Watch the "What This Means" video here FRAMINGHAM, MA / ACCESSWIRE / December 17, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a b...
Neutral
Accesswire
13 days ago
Company continuing to advance DNase-based oncology program towards clinical proof-of-concept studies in multiple indications FRAMINGHAM, MA / ACCESSWIRE / December 16, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat cancers, today announced it has extend...
Neutral
Accesswire
24 days ago
Collaboration utilizes PeriNess' expertise in clinical development of human recombinant DNase and bolsters efforts towards clinical proof-of-concept studies in multiple indications FRAMINGHAM, MA / ACCESSWIRE / December 5, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressi...
More Xenetic Biosciences, Inc. News

Company Profile

Xenetic Biosciences, Inc. engages in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient's malignant tumor cells. Its product pipeline includes XCart Platform and Polyxen. The company was founded on August 9, 2011 and is headquartered in Framingham, MA.

Head office United States
CEO James Parslow
Employees 4
Founded 2011
Website www.xeneticbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today